EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Real-World Effectiveness of Upadacitinib for Perianal Crohn’s Disease: A Multicenter Retrospective Study

Jalpa Devi, Anish Patel, Baseer Quraishi, Bharati Dev, Tingyi Tan, Meredith Kline, Navreet Chowla, Prajith Raj Ramesh, David H Ballard, Lulu Huang, Fnu Jaiprada, Sami Samaan und 22 weitere

Clinical Gastroenterology and Hepatology · 2026-05

DOI: 10.1016/j.cgh.2026.05.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Jalpa Devi und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, University of Nebraska Medical Center, Omaha, Nebraska; Division of Gastroenterology, Washington University School of M…. Hauptthemen laut MEDLINE: Crohn Disease, Janus Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS, The Leona M and Harry B Helmsley Charitable Trust, NIH NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: A post-hoc analyses of phase III trials showed efficacy of upadacitinib in perianal Crohn's disease, but real-world effectiveness is scarce, and radiologic response has not been reported previously. This study evaluated clinical and radiologic outcomes of patients with perianal Crohn's disease treated with upadacitinib. METHODS: In this multicenter retrospective cohort study, adults with active perianal Crohn's disease treated with upadacitinib across 10 North American centers were included. The primary outcome was clinical response, defined as a ≥3-point reduction in the Perianal Disease Activity Index. Secondary outcomes included clinical remission (Perianal Disease Activity Index ≤4 and ≥3-point decrease or no worsening), ≥50% C-reactive protein reduction, pelvic magnetic resonance imaging outcomes (per TOpClass criteria), and rates of hospitalization, antibiotic use, and perianal Crohn's disease-related surgery. Subgroup and Cox regression analyses assessed the effect of perianal Crohn's disease duration, Montreal classification, prior biologic and anti-tumor necrosis factor exposure. RESULTS: Among 125 patients (56% male, median age 33 years), 48% had complex fistulas and 77.4% had prior anti-tumor necrosis factor exposure. At follow-up, 45.5% achieved clinical response, 39.4% clinical remission, 5.1% were hospitalized, and 13.1% underwent perianal surgery. On pelvic magnetic resonance imaging (n = 78), 55.1% improved and 11.5% completely healed. Clinical response was higher in anti-tumor necrosis factor-naïve patients with perianal Crohn's disease (66.7% vs 33.3%; P = .001) and those with shorter disease duration (54.7% vs 33.3%; P = .04). Prior anti-tumor necrosis factor exposure predicted lower clinical response (hazard ratio, 0.38; 95% confidence interval, 0.22-0.66; P < .001). CONCLUSIONS: Treatment with upadacitinib was associated with improved fistula outcomes in patients with perianal Crohn's disease, with greater effectiveness in those anti-tumor necrosis factor-naïve or with shorter disease duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseJanus Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedYoung AdultHeterocyclic Compounds, 3-RingMagnetic Resonance ImagingNorth AmericaRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Fistula HealingPerianal Crohn’s DiseaseReal-World EffectivenessUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingupadacitinibJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, University of Nebraska Medical Center, Omaha, Nebraska; Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri.
  • Division of Gastroenterology, Brooke Army Medical Center, San Antonio, Texas.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside/West, New York, New York.
  • Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri.
  • Division of Gastroenterology, Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Förderung

  • NCATS
  • The Leona M and Harry B Helmsley Charitable Trust
  • NIH NCI
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company

Zitieren

APA

Devi, J., Patel, A., Quraishi, B., Dev, B., Tan, T., Kline, M., Chowla, N., Ramesh, P. R., Ballard, D. H., Huang, L., Jaiprada, F., Samaan, S., Stone, M., Khan, A., Seeraj, A. A., Alanazi, S., Xu, A., Maas, L., Jajoo, A., …, & Deepak, P. (2026). Real-World Effectiveness of Upadacitinib for Perianal Crohn’s Disease: A Multicenter Retrospective Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.05.003

Vancouver

Devi J, Patel A, Quraishi B, Dev B, Tan T, Kline M, et al. Real-World Effectiveness of Upadacitinib for Perianal Crohn’s Disease: A Multicenter Retrospective Study. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.05.003

BibTeX
@article{Devi2026,
  author = {Devi, Jalpa and Patel, Anish and Quraishi, Baseer and Dev, Bharati and Tan, Tingyi and Kline, Meredith and Chowla, Navreet and Ramesh, Prajith Raj and Ballard, David H and Huang, Lulu and Jaiprada, Fnu and Samaan, Sami and Stone, Molly and Khan, Abdul and Seeraj, Alyssa Anita and Alanazi, Sami and Xu, Anthony and Maas, Laura and Jajoo, Arpita and Parian, Alyssa and Altinmakas, Emre and Ehman, Eric C and Davenport, Matthew S and Li, Sophia and Chithriki, Mamata and Shukla, Richa and McCurdy, Jeff and Yarur, Andres J and Bishu, Shrinivas and Johnson, Amanda M and Benjamin, McDonald and Dulaney, David and Serre-Yu, Wong and Deepak, Parakkal},
  title = {Real-World Effectiveness of Upadacitinib for Perianal Crohn’s Disease: A Multicenter Retrospective Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.05.003}
}
Kostenlos starten →